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Inhibition of Amyloid b-Protein Production
in Neural Cells by
the Serine Protease Inhibitor AEBSF
M. Citron,* T. S. Diehl,* A. Capell,* Seubert et al., 1992; Shoji et al., 1992). At least two
protease activities must be involved in Ab generation.C. Haass,‡ D. B. Teplow,† and D. J. Selkoe*
Proteases referred to as b- and g-secretases cleaveDepartment of Neurology
at the N-terminus (at a Metrhione–Aspartate [Met–Asp]Harvard Medical School
bond) and at the C-terminus (around residues 40–42*Center for Neurologic Diseases
of Ab), respectively (Figure 1). There is evidence that†Biopolymer Laboratory
b-secretase cleaves first, leading to the secretion ofBrigham and Women’s Hospital
b-APPs (Seubert et al., 1993) and the retention of a 12Boston, Massachusetts 02115
kDa membrane-bound fragment. The latter is believed‡Zentralinstitut fu¨r seelische Gesundheit
to give rise to Ab, following cleavage by g-secretaseUniversity of Heidelberg
(Cai et al., 1993; Citron et al., 1995). g-secretase hasMannheim 68159
also been suggested to be capable of cleaving theFederal Republic of Germany
a-secretase-generated 10 kDa-C-terminal fragment,
giving rise to a 3 kDa-secreted fragment (p3) (Haass et
al., 1993) (Figure 1). Evidence confirming these precur-Summary
sor-product relationships has recently been presented
(Higaki et al., 1995). In addition to the a- and b-secretoryCerebral deposition of amyloid b protein (Ab) is an
pathways, a substantial portion of full-length bAPP mol-early and critical feature of Alzheimer’s disease. Ab
ecules seems to be degraded in the lysosomal systemproduction requires the proteolytic release of Ab from
(Golde et al., 1992, Soc. Neurosci., abstract; Haass etthe b-amyloid precursor protein (bAPP). Thus, inhibi-
al., 1992a).tion of Ab release is a prime therapeutic goal. Here,
As an initial step toward characterizing the proteaseswe show that the broad spectrum, irreversible serine
involved in bAPP processing, several studies have ex-protease inhibitor, AEBSF, inhibits the constitutive
amined the sequence specificity of a- and b-secretasesproduction of Ab in five different human cell lines, both
in different cell types. For a-secretase, it was shownneural and nonneural. AEBSF also stabilizes full-length
that alternative cleavage sites within the Ab region can
bAPP and enhances a-secretion, as shown by an in-
be used in different cells, suggesting that a-secretasecrease in the proteolytic derivative, a-APPs. Further, is likely to involve a diverse set of proteases (Zhong etwe demonstrate that the inhibitory effect of AEBSF is
al., 1994). It has been further suggested that a-secretasespecific for Ab proteins starting at Aspartate 1, sug-
recognizes only membrane-bound bAPP and that thegesting that AEBSF directly inhibits b-secretase, the
principal determinant of this scission is an a-helical con-
Methionine–Aspartate (Met–Asp)-cleaving enzyme.
formation around the cleavage site, not the primary
These results indicate that specific inhibition of this
structure of this region (Sisodia, 1992). Missense muta-
Ab-generating protease is possible in living human
tions bordering the a-secretase site, e.g., the naturallyneural cells and provide information about the charac-
occuring A692G mutation associated with familial AD in
teristics of this as yet unidentified enzyme.
a Flemish kindred (Hendriks et al., 1992), influence bAPP
processing by increasing the Ab/p3 ratio (Haass et al.,
Introduction 1994a). This effect is particularly striking in the artificial
mutant F690P, in which all of the products of a-secretory
The pathogenesis of Alzheimer’s disease involves the processing, a-APPs, the 10 kDa-C-terminal fragment,
early and invariant formation of extracellular amyloid and p3, are strongly decreased, and Ab-like peptides
plaques in the cerebral and limbic cortices. These starting predominantly at positions other than Asp1 be-
plaques are predominantly composed of the 4 kDa amy- come the major Ab species (Haass et al., 1994a).
loid b-protein (Ab). Ab is proteolytically derived from an As in the case of a-secretase, b-secretase cleavage
integral membrane polypeptide termed the b-amyloid occurs at slightly different positions within bAPP in dif-
precursor protein (bAPP) (Kang et al., 1987). bAPP can ferent cell types (Citron et al., 1994; Haass et al., 1994b;
be cleaved by multiple proteases to yield a variety of Haass et al., 1992b), suggesting that distinct cell-spe-
secreted and membrane-bound derivatives (for review, cific proteases are capable of generating the N-termini
see Selkoe, 1994). The predominant cleavage is medi- of Ab. Again, as for a-secretase, only membrane-bound
ated by an unknown protease designated a-secretase, APP substrates are cleaved by b-secretase in intact
leading to the secretion of the large NH2-terminal ecto- cells in culture (Citron et al., 1995). The Swedish FAD
domain of bAPP called a-APPs (Weidemann et al., 1989), mutation, immediately N-terminal to the b-secretase
and the retention of a 10 kDa COOH-terminal fragment cleavage site (Mullan et al., 1992), causes a 3–6-fold
in the cell membrane (Selkoe et al., 1988) (Figure 1). This increase in Ab production (Cai et al., 1993; Citron et
a-secretory cleavage is considered nonamyloidogenic al., 1992; Citron et al., 1994), while p3 production is
because it occurs within the Ab domain (Esch et al., decreased (Citron et al., 1992). Concomitantly, b-APPs
1990; Wang et al., 1991). is increased and a-APPs is decreased (Felsenstein et
An alternative proteolytic mechanism leads to the al., 1994). However, most other amino acid substitutions
constitutive secretion of Ab by human mixed brain cul- introduced at or immediately surrounding the b-secre-
tase cleavage site strongly decrease Ab production ortures and a variety of cell lines (Haass et al., 1992b;
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by treating cells with leupeptin (Haass et al., 1993) or
with the broad spectrum cysteine protease inhibitor E64
(Higaki et al., 1995).
Here, we show that the general serine protease inhibi-
tor 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF)
(Kazmirowski, 1971) strongly and reproducibly de-
creases Ab production in a variety of different cell types,
while p3production isunaffected or increased. We dem-
onstrate that this inhibition occurs only in cells that
produce Ab starting at Asp1, not in cells producing Ab-
related proteins starting predominantly at other N-ter-
mini. We hypothesize that AEBSF directly inactivates a
serine protease type b-secretase enzyme that cleaves
at Met–Asp to generate the conventional N-terminus
of Ab.
Results
AEBSF Inhibits Ab Production in a Variety
of Cell Lines
K293 human embryonic kidney cells stably transfected
with bAPP695 carrying the Swedish mutation (K695sw)
were metabolically labeled for 2 hr and chased for 2 hr
in the presence of increasing concentrations of AEBSF.
To exclude differential degradation of secreted material
after collection of the treated versus untreated media,
all media were brought to a final concentration of 1 mM
AEBSF immediately after the 2 hr chase. Media were
then immunoprecipitated with the Ab (1–40) specific
polyclonal antibody R1282. A dose-dependent decrease
Figure 1. bAPP Structure and Processing of Ab was observed (Figure 2A). In this paradigm, Ab
The schematic shows bAPP695 with the large N-terminal ectodomain accumulation was inhibited 50% (IC50) at an AEBSF
in gray stripes, the Ab region in black, and the C-terminus in white
concentration of z1 mM (Table 1). This dose was then(not drawn to scale). The regions to which antibodies were raised
used for all further quantitations in K293-derived cellare indicated by bars on top. Full-length bAPP molecules undergo
lines. Under the same conditions, p3 production was notN- and O-glycosylation, and can either be completely degraded
intracellularly or processed by a-secretase to yield secreted a-APPs decreased (Figure 2). To analyze whether the observed
and a membrane-bound 10 kDa fragment, or by b-secretase to yield effect was specific for bAPP with the Swedish mutation,
secreted b-APPs and a membrane-bound 12 kDa fragment. These we performed the same experiment with K293 cells sta-
membrane-bound fragments can each undergo g-secretase cleav-
bly transfected with wild-type bAPP695 (K695 cells).age to give rise to the secreted fragments Ab and p3. The hypotheti-
Again, a dose-dependent decrease of Ab productioncal p7 fragment has not yet been detected. AEBSF appears to block
was observed; however, the inhibition of Ab productionboth the degradation of full-length bAPPmolecules and the b-secre-
tory pathway. was less pronounced (Figure 2B; Table 1). In these cells,
AEBSF led to an increase in p3 levels.
To determine how general the inhibition of Ab produc-
tion was, we studied three additional cell lines. HS695,shift the cleavage to another position, indicating that
b-secretase exhibits high-sequence specificity. A typi- a human glioma cell line, and SKN695, a human neuro-
blastoma cell line, were each stably transfected withcal mutation of this class, D597D, not only eliminates
the Asp1 protein but leads to significant production of wild-type bAPP695. In addition, primary human skin fibro-
blasts cultured from a subject carrying the Swedishan Ab species starting at Phe4 (Citron et al., 1995).
For both a- and b-secretases, a wide variety of candi- bAPP mutation were studied. All three of these cell lines
showed the same qualitative effect of AEBSF, i.e., adate proteases have been suggested, largely based on
their ability to cleave synthetic substrates that mimic dose-dependent decrease of Ab production. However,
the IC50 was substantially lower than 1 mM, generallythe native APP cleavage site (for review, see Evin et al.,
1994). The physiological relevance of these candidate in the z 300 mM range, for both HS695 and SKN695
(Figures 2C and 2D; Table 1). In general, p3 was constantenzymes has not been demonstrated, for example, by
inhibiting their enzymatic activity in intact cells and or increased, however, in the more sensitive HS695 line,
doses of AEBSF above the IC50 for Ab led to a decreaseshowing a corresponding decrease in Ab or p3 produc-
tion. An inhibitor that acts directly on the production of in p3 production, as well (Figure 2C). In the primary
Swedish fibroblasts, almost no p3was observed withoutAb or p3 in intact living cells would be highly useful
for isolating and characterizing the relevant proteases drug treatment (Figure 2E), as has been described pre-
viously (Citron et al., 1994). Wild-type primary fibroblastsinvolved in bAPP processing. Previous studies have al-
ready demonstrated that Ab production is not affected also showed an inhibition of Ab and an increase in p3
Inhibition of Ab Production by AEBSF
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Table 1. Effect of AEBSF and bAPP Metabolites in Seven
Different Cell Lines
Metabolite
Cell Line Ab a-APPs fl-APP
K695sw 0.49 6 0.04 3.0 6 0.6 2.3 6 0.6
K695 0.71 6 0.05 4.8 6 1.3 1.8 6 0.4
HS695 0.37 6 0.22 1.8 6 1.1 1.7 6 0.4
SKN695 0.57 6 0.11 1.7 6 0.5 6.2 6 1.7
Fibro 0.39 6 0.12 1.5 6 0.3 7.7 6 1.6
F690P 1.56 6 0.48 6.6 6 1.6 3.3 6 0.7
D597D 1.52 6 0.16 2.4 6 1.1 3.7 6 0.2
For each metabolite, the numbers show the amount relative to un-
treated controls (1.0). All data are means 6 standard deviation of
three different experiments quantitated by phosphorimaging. HS695
and SKN695 were treated with 300 mM AEBSF, while all other lines
were treated with 1 mM AEBSF. b-APPs in K695sw is 0.73 6 0.04
of the untreated control.
as well as in immature N’-glycosylated bAPP, and
showed some increase in the 10 kDa C-terminal frag-
ment. (Figure 3; Table 1). These datasuggest that AEBSF
inhibits intracellular degradation of bAPP and its a-se-
cretase generated C-terminal fragment. The strong in-
crease in immature N’-glycosylated bAPP695 suggests
that a major proportion of this species is normally de-
graded intracellularly before becoming fully O-glycosy-
lated.
AEBSF Increases a-Secretion but Inhibits
b-Secretion of APPs
To exclude the possibility that the observed decrease
of Ab levels was due to a general, nonspecific inhibition
of protein secretion, aliquots of the total conditioned
media used for the dose response experiment with
K695sw cells were run on a gel without immunoprecipi-
tation. Increasing doses of AEBSF did not alter the re-
Figure 2. Dose-Dependent Inhibition of Ab Production sulting autoradiogram of the major secreted proteins
The indicated human cell lines were labeled and then chased in (data not shown), indicating that under the conditions
media with increasing concentrations of AEBSF (in mM). Media were
of the experiment, AEBSF does not generally decreaseimmunoprecipitated with R1282.
the release of secreted proteins. For all cell lines ana-
lyzed, aliquots of the same media that had been immu-
noprecipitated with 1282 weresubjected to precipitationproduction (data not shown). Finally, inhibition of Ab
by AEBSF was observed in bAPP695- and bAPP695sw- with antibody 1736, which selectively recognizes only
a-cleaved APPs. At the IC50 for Ab, a-APPs was in-transfected CHO cells (data not shown). In summary,
all eight wild-type and Swedish mutant cell lines we creased between 1.5–4.8-fold in every line (Figure 4;
Table 1). Thus, AEBSF does not inhibit the a-secretoryexamined showed a dose-dependent inhibition of Ab
production. At the IC50 for Ab, p3 was not significantly pathway, and accordingly, p3 was not decreased.
If AEBSF directly inhibits b-secretase cleavage, itdecreased. Interestingly, the K695sw line showed a
larger reduction in Ab than the corresponding wild-type should not only reduce Ab but also b-APPs. Likewise,
the 12 kDa fragment, which has been shown to be the293 line, which exhibited the least Ab inhibition of all
the cell lines analyzed (see below). immediate precursor of Ab that has not yet undergone
g-secretase cleavage (Cai et al., 1993; Citron et al., 1995;
Higaki et al., 1995), should be reduced. However, theAEBSF Stabilizes Cell-Associated Full-Length
bAPP and Its C-Terminal Fragments standard 2 hr pulse/2 hr chase paradigm optimized for
Ab detection would not necessarily reflect this reductionTo assess whether cell-associated full-length bAPP was
also affected by AEBSF, cell lysates of the 5 lines shown in 12 kDa production, if AEBSF also interferes with the
general degradation of bAPP and its C-terminal frag-in Figure 2 were immunoprecipitated with antibody C7
(to the bAPP C-terminus) after a 2 hr pulse-chase experi- ments, as suggested above. Therefore, we modified the
pulse chase protocol to keep intracellular degradationment. To exclude differential bAPP degradation after
cell lysis, all extracts were prepared with a lysis buffer to a minimum. K695sw cells were pulse labeled for 10
min, chased in the absence of AEBSF for 25 min andthat contained 1 mM AEBSF. All five lines exhibited a
large increase in mature N’- and O’- glycosylated bAPP, then chased for another 20 min in the presence of
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Figure 3. AEBSF Stabilizes Full-Length bAPP
The indicated cell lines were labeled and then chased in media with the indicated concentration of AEBSF (in mM). Cell lysates were precipitated
with the C-terminal antibody C7.
AEBSF. This timing introduces AEBSF when most of that in a short pulse-chase, all b-secretase cleavage
products are decreased by AEBSF treatment as ex-the labeled Swedish bAPP molecules are undergoing
b-secretase cleavage, according to recent pulse-chase pected, whereas the other APP metabolites are unaf-
fected or increased.studies conducted in these cells (Walter et al., 1996).
The short chase in the presence of the inhibitor does not
allow much reinternalization of bAPP or its C-terminal
fragments to occur. This experiment was done with the AEBSF Inhibits Met–Asp Cleavage
If a Met–Asp-cleaving b-secretase enzyme is directlyK695sw cells because they express high amounts of
Swedish bAPP, of which a large proportion undergoes inhibited by AEBSF, as the above results suggest, one
would observe a decrease in total Ab generation. Theb-secretase cleavage and because the b-secretase-
derived APPs-species (b-APPs) is readily detectable with extent of this decrease should depend on the relative
contribution of the inhibited Met–Asp-cleaving protease192sw (Haass et al., 1995; Knops et al., 1995). As ob-
served in the long chase experiments, a-APPs (precipi- to total Ab production from a particular bAPP substrate
in a particular cell line. In this regard, the K293 cellstated by 1736) is increased by AEBSF (Figure 5A; Table
2). However, b-APPs (precipitated by 192sw) was clearly transfected with APP695sw (K695sw) would be expected
to show a more pronounced decrease in total Ab thandecreased (Figure 5B; Table 2), as was Ab, while p3 was
increased (Figure 5C; Table 2). The 12 kDa fragment K293 cells transfected with wild-type APP695 since in
K695sw cells, the N-terminus of Ab has been shown towas assessed by precipitating it from cell lysates using
the Ab antibody 1282 (Figure 5D). The N-terminal se- start exclusively at Asp 1 (Citron et al., 1994), whereas
in K695 cells, which express wild-type APP, about 20%quence of this band has previously been confirmed by
radiosequencing, indicating that it starts at Asp1 (data of the total Ab species generated begins at positions
other than Asp 1 (Haass et al., 1992b), presumably asnot shown). Interestingly, 1282 did not precipitate the
10 kDa fragment (Figure 5D), which often overshadows a result of cleavages by different proteases (Citron et
al., 1995). Thus, compensatory cleavage by these unin-the 12 kDa fragment in C7 precipitations (Figure 5E). In
the presence of AEBSF, the 12 kDa fragment was hibited proteases could account for the relatively mod-
est Ab decline observed in K695 cells after AEBSF com-strongly reduced (Figure 5D; Table 2), while the 10 kDa
fragment and full-length APP were not decreased (Fig- pared to the other cell lines examined above (Table 1),
all of which show almost exclusively Asp 1 cleavageure 5E;Table 2). Taken together, these data demonstrate
Figure 4. AEBSF Increases a-Secretion
The indicated cell lines were labeled and then
chased in media with the indicated concen-
tration of AEBSF (in mM). Aliquots of the
chase media were precipitated with antibody
1736, which specifically recognizes a-APPs.
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Figure 5. AEBSF Decreases b-Secretase
Cleavage
K695sw cells were pulse labeled for 10 min,
then chased for 25 min in medium without
AEBSF. The medium was then adjusted to
the indicated concentration of AEBSF (in mM)
and the chase continued for another 20 min.
(A) An aliquot of the chase media was precipi-
tated with antibody 1736, which specifically
recognizes a-APPs.
(B) Another aliquot was precipitated with anti-
body 192sw, which specifically recognizes
b-APPs. Note the lower molecular weight of
this shortened form of APPs.
(C) A third aliquot of the same media was
precipitated with the Ab antibody 1282.
(D) An aliquot of the lysates was precipitated
with 1282 to detect the 12 kDa fragment. Note
that no intracellular Ab was detectable in the
lysates.
(E) A second aliquot of the lysateswas precip-
itated with the C-terminal antibody C7.
(Citron et al., 1994); (M. C. and D. B. T., unpublished showed that AEBSF leads to an increase in Ab-like pro-
teins starting at Phe 4, Val 23, Ile 26, and Arg 5, butdata).
To test this hypothesis, we analyzed two K293 lines no substantial change of conventional Ab starting at
Asp 1 (Figure 7A). Similar results were obtained for thethat were transfected with mutated bAPP and produce
Ab-like peptides that start predominantly at positions 293 cell line D597D, which stably expresses bAPP695 with
a deletion of codon D597. This cell line has previouslyother than Asp 1. The cell line F690P is stablytransfected
with bAPP695 carrying the mutation F690P (bAPP770 been shown to produce Ab-like peptides starting exclu-
sively at Phe 4 (Citron et al., 1995) (Figure 7B). Fl-APP,numbering). This cell line has been shown to produce
some Ab starting at Asp 1, but mainly Ab-like peptides the 10 kDa fragment, p3, and a-APPs were all increased
by AEBSF, as in wt APP transfectants, and total Ab-starting at other positions and almost no p3 (Haass et
al., 1994a) (Figure 7A). Treatment of the F690P cells with like peptides were again increased in a dose-dependent
manner (Figure 6B; Table 1). Radiosequencing of totalAEBSF resulted in the usual increase of fl-APP and its
10 kDa fragment (Figure 6A). Likewise, p3 and a-APPs Ab from the D597D line showed a strong increase in the
Phe 4 species upon AEBSF treatment (Figure 7B). Inwere increased (Figure 6A) as described above for the
other 293 derived cell lines. However, total Ab proteins contrast, radiosequencing of AEBSF-treated K695sw
cells demonstrated only the Asp 1 peak (data notwere actually increased in a dose-dependent manner
(Figure 6A; Table 1). Radiosequencing of secreted Ab shown), indicating that in this cell line, secretion of alter-
native Ab proteins does not compensate for the de-from both AEBSF-treated and untreated F690P cells
crease in the Asp 1 form.
Thus, in the identical cellular background of a cloned
Table 2. Effect of 1 mM AEBSF on bAPP metabolites of K695sw 293 line, the same dose of AEBSF can lead to a 50%
cells in a short pulse chase increase of Ab-like proteins that start at positions other
Metabolite Relative Amount than Asp 1, but to a 50% decrease of conventional Ab
starting at Asp 1. These results strongly suggest thatAb 0.28 6 0.05
AEBSF specifically inhibits the proteolytic generation ofp3 1.48 6 0.39
a-APPs 1.76 6 0.23 Ab starting at Asp 1.
b-APPs 0.44 6 0.07
fl-APP 1.02 6 0.13
12 kDa fragment 0.27 6 0.16 Discussion
10 kDa fragment 1.03 6 0.43
All detectable bAPP metabolites were analyzed. The numbers show Several lines of evidence strongly support the hypothe-
the amount relative to untreated controls (1.0). All data are means sis that progressive cerebral deposition of Ab is a semi-
6 standard deviation of three different experiments quantitated by nal event in the pathogenesis of Alzheimer’s disease
phosphorimaging.
(for review, see Selkoe, 1994). Therefore, interest is
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Figure 6. AEBSF Increases Ab Production in
the Cell Lines F690P and D597D
The cell lines F690P (A) and D597D (B) were
labeled and then chased in media with in-
creasing concentrations of AEBSF (in mM).
Media were immunoprecipitated with R1282.
Aliquots were precipipitated with 1736, and
cell lysates were precipitated with the C-ter-
minal antibody C7. The positions of N’ and
N’1O’ glycosylated full-length bAPP and of
the 10 kDa fragment are indicated.
growing in developing pharmacological inhibitors of the APP, and potentially of APPs, is fully degraded before
it reaches the cell surface. These findings are consistentproteases responsible for constitutively generating Ab
from bAPP, i.e., the so-called b- and g-secretases. Al- with the data of Kuentzel et al. (1993), who suggested
that 70%–80% of synthesized immature bAPP is de-though several known enzymes have been proposed as
candidates for these proteases, definitive identification graded, probably within the endoplasmic reticulum as
described for other proteins (Klausner and Sitia, 1990).of the responsible enzymes has not yet been reported.
It is important to identify the correct b-secretase, the Thus, AEBSF appears to be capable of blocking both
nonspecific intracellular APP metabolism and theprotease thought to be responsible for initiating Ab gen-
eration (Cai et al., 1993; Citron et al., 1995), and to dem- b-secretase-processing pathway.
Of particular importance are the results of radio-onstrate its inhibition under biologically relevant condi-
tions, i.e., in intact human cells. Here, we report that the sequencing of secreted Ab, which show that AEBSF
specifically inhibits the protease(s) capable of generat-serine protease inhibitor, AEBSF, decreases the secre-
tion of Ab by five different cell types, including three ing Ab peptides starting at Asp1. This specificity was
demonstrated by the observation that AEBSF inhibitedhuman cell lines and primary fibroblasts cultured from
normalsubjects, and from AD patients harboring a bAPP production of the major Ab peptide beginning at Asp
1, resulting in enhanced production of Ab-like proteinsmissense mutation. This decrease in secretion is due to
a decrease in Ab production, not a block in release, beginning at alternative N-termini. Although AEBSF is
clearly a broad spectrum serine-protease inhibitor, itbecause extracts of treated cells do not show any accu-
mulation of Ab intracellularly (Figure 5D). shows a differential effect on the several as yet unde-
fined proteolytic activities (b-secretases) that constitu-Analysis of the production of full-length bAPP and its
principal proteolytic derivatives shows that AEBSF does tively process bAPP holoproteins at or near the Ab
N-terminus. The most straightforward explanation fornot lower Ab by a nonspecific or cytotoxic mechanism,
because the levels of full-length bAPP are stabilized and the effects reported here is that AEBSF selectively inhib-
its a b-secretase activity that cleaves the Met–Asp bondthe secretion of a-secretase-generated products, i.e.,
a-APPs and p3, is not decreased, whereas b-secretase at the N-terminus of Ab. In particular, using K695sw
cells, we could demonstrate a decrease not only in Abcleavage products are reduced. Importantly, the secre-
tion of proteins in general is not reduced by AEBSF but also in the direct products of Met–Asp-b-secretase
cleavage, namely b-APPs and the 12 kDa fragment. Inunder the conditions of our experiments. The striking
increase in full-length APP and a-APPs by AEBSF sug- several cell lines, we observed a concomitant increase
of alternative b-secretase-like N-terminal cleavages,gests that in normal cells, a major portion of full-length
Inhibition of Ab Production by AEBSF
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Figure 7. Radiosequencing of Ab Proteins
Secreted by the Cell Lines F690P and D597D
with and without AEBSF Treatment
The 3H-phenylalanine radioactivity obtained
at each cycle of the Edman chemistry is
graphed for untreated samples (dashed lines)
and treated samples (continuous lines). The
sequences above the graphs are correct for
the predominant species, i.e., Val 23 for
F690P (A) and Phe4 for D597D (B). The radio-
labeled phenylalanines are italicized. In (A),
the Ab species represented by the major
peaks are indicated above the peaks.
supporting our previous evidence that the Met–Asp- cholinergic agonists (Buxbaum et al., 1993; Hung et al.,
1993), because the PKC inhibitor staurosporine doescleaving b-secretase is a highly sequence-specific pro-
tease that is unlikely to be responsible for creating the not reverse the effect of AEBSF (data not shown). In this
work, AEBSF has been used only in the most informativealternative Ab N-termini observed in some cell types
(Citron et al., 1995). In the majorityof cell types examined pulse chase format to focus on APP-processing effects.
Continuous labeling in the presence of the compoundthat almost exclusively produce Ab beginning at Asp 1,
AEBSF causes only a decrease in total Ab secretion. leads to a decrease in all APP metabolites (data not
shown), probably due to some general interference withPresumably, such cell types lack the proteases or traf-
ficking mechanisms necessary to generate alternative synthesis of the protein. The short pulse chase used
for K695sw clearly demonstrates that all b-secretase-Ab N-termini, even when the major N-terminal cleavage
is prevented. The enhanced production of a-secretase- cleavage products are reduced and does not show any
accumulation of intracellular Ab, therefore ruling out themediated products of bAPP that AEBSF induces sug-
gests that inhibition of the major b-secretase (and other possibility that AEBSF only interferes with secretion of
Ab into the medium rather than its production byserine proteases) provides more bAPP substrate for
a-secretase cleavage. b-secretase cleavage. However, this still leaves open
the possibility that AEBSF inhibits a serine protease thatAlthough the selective inhibition of a Met–Asp-cleav-
ing b-secretase activity by AEBSF is consistent with proteolytically activates b-secretase. We believe this
possibility is unlikely, because b-secretase appears tothe data reported here, we cannot exclude alternative
mechanisms. For example, it is possible that inhibition be constitutively active, requiring us to postulate a very
short half life of an activated b-secretase, since AEBSFof serine proteases by AEBSF, or another action of this
compound, could alter bAPP trafficking rather than di- acts within 20 min in our experiments.
It is important to emphasize that AEBSF itself or re-rectly inhibiting the Met–Asp-b-secretase activity. How-
ever, we have at least ruled out the possibility that lated compounds would be unlikely to be pharmaceuti-
cally useful for Ab inhibition in vivo, given their nonspe-AEBSFreduces Ab production by protein kinase C (PKC)
activation, as has been described for phorbolesters and cificity and multiple cellular actions. Nonetheless, the
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two 10 cm dishes, pulse labeled with 1 mCi of [35S]-methionine in 4findings reported here demonstrate that inhibition of a
ml of serum-free medium per dish for 10 min and chased for 25 minprotease that selectively generates the major Ab
with medium containing 10% fetal bovine serum. Then, AEBSF wasN-terminus (Asp 1) and thus initiates Ab production can
added and the chase continued for another 20 min. Conditioned
be achieved in a variety of human cell types. Therefore, media and cell lysates were analyzed by immunoprecipitation, as
it may be possible to find alternative serine protease described (Haass et al., 1992b). Polyclonal antibody R1736 to resi-
dues 595–611 of APP695 was used to precipitate a-APPs (Haass etinhibitors that have far greater selectivity of action than
al., 1994a) This antibody recognizes an epitope that is specific forAEBSF and act principally upon b-secretase. Moreover,
the free C-terminus of a-cleaved APPs. Polyclonal antibodies R1280our results suggest that AEBSF or homologous com-
(Tamaoka et al., 1992) and R1282 were generated to synthetic Ab1–40.pounds could be useful as tools during the purification
They precipitate Ab and p3 (and small, variable amounts of APPs)
and subsequent characterization of Met–Asp-b-secre- from the media of cultured cells (Haass et al., 1992b). The polyclonal
tase enzymes from human cells. For example, radiola- antibody C7 against the last 20 residues of the bAPP cytoplasmic
tail (Podlisny et al., 1991) precipitates N’- and N’ plus O’-glycosy-beled AEBSF or a similar molecule might prove useful
lated full-length bAPP as well as itsC-terminal proteolytic fragments.for identifying subcellular fractions enriched in this type
The antibody sw192 (Knops et al., 1995) specifically precipitatesof b-secretase and for following the quantity and quality
b-cleaved APPs carrying the Swedish mutation. Electrophoresis ofof a candidate protease during its purification. It will be
immunoprecipitates of cell extracts or of Ab from media was done
interesting to see whether previously proposed candi- on 10%–20% Tris-Tricine gels (Novex), while APPs precipitates were
date proteases, e.g., the Ca-activated serine protease electrophoresed on 10% SDS-polyacrylamide Tris Glycine gels. All
quantitations were performed with a Phosphorimager 400A, using(Razzaboni et al., 1992) would be identified in all cells
Image-QuaNT software (Molecular Dynamics).in which AEBSF inhibits Ab production. Our results also
suggest that the pharmacological screening of human
cell lines stably overexpressing bAPP, particularly cell Radiosequencing
For each radiosequencing experiment, cells in two confluent 10 cmlines such as 293, which are capable of producing sev-
dishes were metabolically labeled for 2 hr with 2 mCi per dish oferal different Ab N-terminal cleavages, could help to
L-[2,3,4,5,6–3H]phenylalanine in phenylalanine-free Dulbecco’sidentify serine protease inhibitors that selectively block
modified Eagle’s medium (DMEM) containing 10% fetal bovine se-
the principal Met–Asp-cleaving protease that is presum- rum (FBS). The cells were then chased with DMEM containing 10%
ably responsible for initiating Ab production. FBS, excess unlabeled phenylalanine, and 1 mM AEBSF. Ab was
immunoprecipitated, electrophoresed, transferred to polyvinylidene
difluoride membrane, and radiosequenced as described (Haass etExperimental Procedures
al., 1992b).
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